IL1RL2 and chronic obstructive pulmonary disease: Our crosstalk experiments show that attenuating the activity of the IL-36R in primary human cells from COPD subjects may also lead to reduced inflammation, suggesting that this may be translated into humans and may be a potential therapeutic option.